Intratumoral PD-1-directed IL-2 expression via oncolytic vaccinia virus elicits superior antitumor effects with enhanced safety - PubMed
5 hours ago
- #Cancer Immunotherapy
- #IL-2 Therapy
- #Oncolytic Virus
- Intratumoral PD-1-directed IL-2 expression via oncolytic vaccinia virus (oVV) enhances antitumor effects with improved safety.
- The study introduces vvDD-PD-1ecto-R-IL-2, a fusion protein combining PD-1 ectodomain and IL-2, to mimic anti-PD-L1 and IL-2 effects.
- The engineered virus aims to transform non-inflamed tumors into immune-inflamed ones, increasing responsiveness to immunotherapy.
- Results show significant antitumor activity, with IL-2 accumulation in the tumor microenvironment boosting immune factors like IFN-γ and reducing protumor factors.
- Treatment expands functional CD8+ T-cell subsets and reduces exhausted T-cell populations, improving tumor immune infiltration.
- The approach minimizes systemic IL-2 toxicity, presenting a promising strategy for clinical cancer immunotherapy.